S713
Clinical – Lower GI
ESTRO 2026
Proffered Paper 2449
reverse K-M methods were used for survival and median follow-up analysis. Cox-regression was used to explore differences in survival between sub-groups. STATA® (v19) was used for analysis. Results: A total of 239 patients were treated with radical intent CRT. Median age was 63 years (IQR 55-71); 67% were female (n=159/239). P16 testing was performed in 56% (133/239) with 91% positivity (121/133). Overall, 20% (n=47) of patients had T4 disease; 77% due to vaginal invasion (n=35) (T4v) and 26% due to invasion into other organs in (n=12). At 6 months, CR was achieved in 71% overall (169/239), 75% in whom response was assessed (n=169/224).Three and five-year PFS were 81% and 78% (median follow-up 4.2 years). Three and five- year OS were 81% and 74% (median follow up 5.1 years). There was no significant difference in PFS (p=0.561) or OS (p=0.822) between patients achieving CR at 3 months and those achieving CR at 6 months.TNM Staging did not significantly affect PFS (p=0.250) or OS (p=0.162). However, when T4 was subdivided, patients with invasion into other organs had significantly worse outcomes, (PFS (p=0.009) and OS (p=0.033)), compared to vaginal invasion only (Figure 1).
Introducing the EORTC QLQ-ANL27, a validated anal cancer-specific health-related quality of life questionnaire Samantha Sodergren 1 , Colin Johnson 2 , Alexandra Gilbert 3 , Anne-Sophie Darlington 1 , Kim Cocks 4 , Marianne Guren 5 , del Campo E Rivin 6 , Peter Christensen 7 , William Chu 8 , Hans Chung 8 , Kristopher Dennis 9 , Isacco Desideri 10 , Duncan Gilbert 11 , Robert Glynne-Jones 12 , Michael Jefford 13 , Mia Johansson 14 , Anders Johnsson 15 , Therese Juul 7 , Dimitrios Kardamakis 16 , Julia Lai-Kwon 13 , Isalia Miguel 17 , Femke Peters 18 , Rachel Simoes Riechelmann 19 , Serdar Turhal 20 , Vassilios Vassiliou 21 1 School of Health Sciences, University of Southampton, Southampton, United Kingdom. 2 Surgery, University of Southampton, Southampton, United Kingdom. 3 Department of Radiation Oncology, Leeds Institute of Medical Research at St James’s, Leeds, United Kingdom. 4 KCStats, Consultancy, Cheshire, United Kingdom. 5 Department of Oncology,, Oslo University Hospital, Oslo, Norway. 6 Department of Radiation Oncology, Tenon University Hospital, Paris, France. 7 Department of Surgery, Aarhus University Hospital, Aarhus, Denmark. 8 Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada. 9 Department of Radiation Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Canada. 10 Radiotherapy Department, University of Florence, Florence, Italy. 11 Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, United Kingdom. 12 Oncology Department, Mount Vernon Cancer Centre, Northwood, United Kingdom. 13 Departments of Medical Oncology and Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 14 Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden. 15 Department of Oncology, Skåne University Hospital, Lund, Sweden. 16 (19) Department of Radiation Oncology, University of Patras Medical School, Patras, Greece. 17 Oncology department, Portuguese Institute for Oncology, Lisbon, Portugal. 18 Netherlands Cancer Institute, Netherlands Cancer Institute, Amsterdam, Netherlands. 19 Oncology department, AC Camargo Cancer Center, Sao Paulo, Brazil. 20 Oncology Department, Anadolu Medical Center, Kocaeli, Turkey. 21 Department of Radiation Oncology, Bank of Cyprus Oncology Center, Nicosia, Cyprus Purpose/Objective: To validate the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire for patients with anal cancer (QLQ-ANL27) treated with chemoradiotherapy (CRT).
Three-year PFS and OS by T-stage was as follows: T1 (92%; 92%), T2 (74%; 84%), T3 (72%; 70%), T4 (80%;79%). Three-year PFS and OS for patients with T4v were 80% and 89%, compared with 47% and 49% for non-vaginal T4 invasion. Conclusion: In this cohort, achieving CR at 6 months rather than 3 months following CRT did not adversely affect survival. However, patients with T4 disease by vaginal invasion had significantly favourable outcomes compared to T4 defined by invasion into other organs. Revision of T4 subclassification may provide better prognostic accuracy. References: 1. Gondal, T. A., et al. (2023). "Anal Cancer: The Past, Present and Future." Curr Oncol 30(3): 3232–3250. Keywords: Anal, Radiotherapy, Response
Made with FlippingBook - Share PDF online